PADI3 and interstitial lung disease: For univariate comparisons of pulmonary outcomes according to antibody status, the prevalence of any ILD was more than double among those with anti-PAD3/4XR compared with the group with no anti-PAD and the group with anti-PAD4 that did not cross-react with PAD3 (both comparisons p<0.05).